| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 303 | 344 | 360 | 392 | 335 | 356 | 350 | 309 | 353 | 404 | 435 | 454 | 412 | 405 | 105 | 367 | 337 | 342 | 402 | 385 | 354 | 426 | 212 | 301 | 364 | 347 | 302 | 279 | 320 |
| Expenses | 263 | 295 | 294 | 321 | 267 | 283 | 266 | 247 | 265 | 300 | 321 | 345 | 315 | 330 | 199 | 349 | 318 | 311 | 350 | 332 | 333 | 393 | 436 | 412 | 322 | 286 | 243 | 228 | 262 |
| EBITDA | 40 | 49 | 66 | 71 | 68 | 73 | 84 | 62 | 88 | 104 | 114 | 109 | 97 | 75 | -94 | 18 | 20 | 31 | 52 | 53 | 21 | 34 | -224 | -111 | 43 | 62 | 59 | 51 | 58 |
| Operating Profit % | 13 % | 14 % | 17 % | 17 % | 19 % | 19 % | 23 % | 17 % | 24 % | 25 % | 25 % | 22 % | 22 % | 18 % | -98 % | 3 % | 4 % | 8 % | 11 % | 13 % | 5 % | 8 % | -106 % | -38 % | 12 % | 18 % | 19 % | 17 % | 18 % |
| Depreciation | 19 | 19 | 21 | 23 | 23 | 24 | 24 | 24 | 26 | 28 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 29 | 28 | 27 | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 |
| Interest | 18 | 20 | 23 | 22 | 19 | 20 | 19 | 20 | 20 | 19 | 21 | 25 | 19 | 17 | 18 | 22 | 23 | 22 | 24 | 22 | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 |
| Profit Before Tax | 3 | 9 | 22 | 26 | 27 | 29 | 41 | 18 | 42 | 57 | 66 | 57 | 50 | 30 | -140 | -31 | -31 | -19 | 1 | 5 | -29 | -17 | -275 | -167 | -14 | 8 | 8 | -2 | 11 |
| Tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33 | -15 | -9 | 0 | 1 | -10 | 0 | 0 | 89 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 3 | 9 | 22 | 26 | 27 | 29 | 41 | 18 | 42 | 57 | 66 | 57 | 50 | 30 | -140 | 2 | -17 | -10 | 0 | 4 | -19 | -17 | -275 | -255 | -14 | 8 | 8 | -2 | 11 |
| EPS in ₹ | 0.23 | 3.47 | 8.96 | 10.17 | 10.29 | 11.21 | 16.00 | 6.78 | 15.75 | 19.21 | 18.47 | 15.57 | 13.95 | 8.27 | -38.93 | 0.53 | -4.56 | -2.77 | 0.12 | 1.05 | -5.43 | -4.77 | -72.07 | -70.93 | -3.50 | 2.54 | 2.03 | -0.93 | 2.46 |
Solara Active Pharma Sciences
Solara Active Pharma Sciences
615.30
-57.10
(-8.49%)
There are 3 new updates from the company1 day ago
View
Market Cap
2,224.60 Cr
EPS
0.14
PE Ratio
90.98
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
882.80
52 Week Low
442.80
PB Ratio
2.05
Debt to Equity
0.89
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Solara Active Pharma Sciences Receives Rs 4.88 Crore Call Money, Converts 3.71 Lakh Partly Paid-Up Shares
Aug 16, 2025
Aug 16, 2025Solara Active Pharma Sciences Limited received first call money of Rs 4,87,95,993.75 for 3,71,779 partly paid-up Rights Equity Shares. The company converted these shares from Rs 3.50 paid-up to Rs 7 paid-up status through a Rights Issue Committee circular resolution. Following this conversion, the company's paid-up capital increased to Rs 44,47,03,723.50. The paid-up capital is now divided into 3,61,54,267 fully paid-up equity shares, 1,17,61,546 partly paid-up Rights Equity Shares with Rs 7 paid-up, and 2,37,209 partly paid-up Rights Equity Shares with Rs 3.5 paid-up. The original rights equity shares were allotted on June 19, 2024, pursuant to a Letter of Offer dated May 09, 2024. The company will take necessary steps for corporate actions and obtaining listing and trading approvals for the converted shares.
Solara Active Pharma Sciences Reports No Deviation in Rights Issue Fund Utilization for Q1 FY26Aug 13, 2025
Solara Active Pharma Sciences Limited submitted its monitoring agency report for the quarter ended June 30, 2025, confirming no deviation in the utilization of Rights Issue proceeds from stated objectives. The company raised Rs 449.95 crore through a Rights Issue conducted from May 28, 2024 to June 11, 2024. CRISIL Ratings Limited, the appointed monitoring agency, reported that Rs 292.75 crore has been utilized out of total net proceeds of Rs 446.95 crore, with Rs 154.2 crore remaining unutilized. The funds were used for repayment of borrowings (Rs 233.61 crore utilized) and general corporate purposes (Rs 59.14 crore utilized). The company repaid loans to HDFC, RBL Bank, Yes Bank, and Radiant Computech. Rs 10.97 crore remains in the monitoring agency account, while Rs 134.99 crore is yet to be raised through a second call planned for FY27.
Solara Active Pharma Sciences delivered revenue of INR320 crores in Q1 FY26, marking 15% quarter-on-quarter growth. The company achieved gross margin of 54% and EBITDA of INR57 crores, reflecting 13% quarterly growth and 36% year-on-year growth. This represents the highest PAT in 12 quarters at INR105 million, with EPS of INR2.5 per share. Developed markets contributed 77% of overall sales. The company reduced debt by INR143 crores, bringing net debt-to-EBITDA ratio to 2.7x. Ibuprofen portfolio contributed approximately 30% of business, down from previous 50% dependency. Management guided for 10% revenue growth and 15-20% EBITDA growth for FY26. The company operates at 60-65% capacity utilization and plans to demerge its CRAMS business with INR200 crores debt allocation.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-0.17 %
Net Income Growth
-100.09 %
Cash Flow Change
95.48 %
ROE
-100.08 %
ROCE
-125.90 %
EBITDA Margin (Avg.)
-339.34 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,822 | 1,960 | 2,154 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 |
| Current Assets | 608 | 648 | 672 | 1,058 | 1,239 | 1,188 | 801 | 729 |
| Capital Work in Progress | 72 | 40 | 41 | 88 | 239 | 239 | 256 | 280 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Other Assets | 663 | 702 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 |
| Total Liabilities | 1,822 | 1,960 | 2,154 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
| Current Liabilities | 738 | 656 | 730 | 789 | 1,063 | 1,101 | 1,243 | 944 |
| Non Current Liabilities | 315 | 344 | 333 | 232 | 354 | 296 | 172 | 191 |
| Total Equity | 769 | 960 | 1,090 | 1,593 | 1,527 | 1,502 | 937 | 1,097 |
| Reserve & Surplus | 739 | 826 | 963 | 1,553 | 1,489 | 1,464 | 898 | 1,054 |
| Share Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 32 | 30 | -20 | 142 | -151 | -38 | -0 | -5 |
| Investing Activities | -86 | -113 | -359 | -106 | -243 | -81 | -4 | -37 |
| Operating Activities | 49 | 166 | 242 | 156 | -242 | 156 | 109 | 213 |
| Financing Activities | 68 | -23 | 97 | 93 | 334 | -113 | -106 | -181 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 44.11 % | 41.07 % | 41.07 % | 39.51 % | 39.71 % | 40.40 % | 40.40 % | 40.40 % | 40.97 % | 39.31 % | 37.19 % | 30.49 % | 30.49 % | 37.27 % | 37.27 % | 37.23 % | 37.94 % | 42.01 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 15.80 % | 14.00 % | 14.25 % | 14.67 % | 14.63 % | 14.25 % |
| DIIs | 3.72 % | 6.18 % | 5.55 % | 5.38 % | 3.39 % | 2.85 % | 2.56 % | 3.01 % | 2.22 % | 1.75 % | 1.75 % | 1.71 % | 2.97 % | 2.83 % | 3.38 % | 3.19 % | 2.61 % | 2.62 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 14.76 % | 14.35 % | 13.84 % | 16.36 % | 17.41 % | 16.61 % | 17.28 % | 16.54 % | 16.23 % | 18.06 % | 19.84 % | 20.95 % | 20.15 % | 19.61 % | 18.83 % | 21.93 % | 23.07 % | 23.47 % |
| Others | 37.41 % | 38.40 % | 39.53 % | 38.73 % | 39.48 % | 40.15 % | 39.76 % | 40.04 % | 40.58 % | 40.88 % | 41.22 % | 46.84 % | 30.59 % | 26.29 % | 26.28 % | 22.98 % | 21.74 % | 17.63 % |
| No of Share Holders | 58,907 | 67,197 | 65,449 | 73,000 | 77,228 | 82,710 | 83,319 | 79,149 | 76,325 | 75,417 | 74,473 | 72,918 | 73,912 | 78,617 | 71,882 | 83,148 | 75,791 | 74,334 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 5 | 2 | 7 | 0.00 | 3 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.22 | 0.16 | 1.14 | 0.00 | 0.88 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Mar 2017 |  Change Of Name | NA | 25 Mar 2017 | 0.00 | 0.00 |
| 20 Aug 2021 |  Dividend | ₹ 3.00 /share | 18 Aug 2021 | 1,484.58 | 1,564.11 |
| 15 May 2024 |  Rights | 1:3 | 15 May 2024 | 465.01 | 503.40 |
| 20 Sept 2024 |  Annual General Meeting | NA | 20 Sept 2024 | 694.40 | 736.35 |
| 21 Oct 2024 |  Quarterly Result Announcement | NA | 21 Oct 2024 | 748.90 | 809.60 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 652.85 | 678.80 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 482.35 | 576.30 |
| 25 Jul 2025 | Quarterly Result Announcement | NA | 25 Jul 2025 | 692.85 | 657.35 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 632.10 | 644.30 |
Announcements
Closure of Trading Window1 day ago
1 day agoAnnouncement Under Regulation 30 SEBI (LODR) - Clarification1 day ago
1 day agoClarification sought from Solara Active Pharma Sciences Ltd1 day ago
1 day agoShareholder Meeting / Postal Ballot-Outcome of AGM2 days ago
2 days agoDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 02, 2025
Sep 02, 2025Reg. 34 (1) Annual Report.Sep 02, 2025
Sep 02, 2025Notice Of The 8Th Annual General MeetingSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Sep 01, 2025Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Aug 21, 2025Receipt Of Call Money Pursuant To The First Reminder Notice Issued For Payment Of First Call Money On The Outstanding Partly Paid-Up Rights Equity Shares Of The Company.Aug 16, 2025
Aug 16, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Jul 25, 2025Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30 2025.Jul 25, 2025
Jul 25, 2025Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.Jul 25, 2025
Jul 25, 2025Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.Jul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Jul 21, 2025Board Meeting Intimation for Quarter Ended June 30 2025 Under SEBI Listing RegulationsJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Dispatch Of First Reminder Notice For Payment Of First Call MoneyJul 02, 2025
Jul 02, 2025Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Appointment Of Internal Auditors Secretarial Auditor And Reappointment Of Cost Auditor.May 15, 2025
May 15, 2025Appointment of Company Secretary and Compliance OfficerMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-RetirementMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
May 15, 2025Statement Of Deviation And VariationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
May 15, 2025Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Announcement Under Regulation 30 - Press ReleaseMay 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
May 08, 2025Board Meeting Intimation for Board Meeting IntimationMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 07, 2025
May 07, 2025Board Meeting Outcome for Board Meeting Outcome For The Rights Issue Committee Meeting - Receipt Of First Call MoneyMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Change in Registered Office AddressMay 05, 2025
May 05, 2025Technical Indicators
RSI(14)
Neutral 40.04
ATR(14)
Volatile 30.16
STOCH(9,6)
Oversold 17.96
STOCH RSI(14)
Oversold 18.47
MACD(12,26)
Bearish -6.03
ADX(14)
Strong Trend 38.99
UO(9)
Bearish 32.63
ROC(12)
Downtrend And Accelerating -7.33
WillR(14)
Oversold -94.80
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.15% | -2 | 0.00% | 0.00% | |
 Aditya Birla Sun Life Flexi Cap Fund Direct-Growth | 0.11% | 0 | 0.00% | 0.00% | |
| Aditya Birla Sun Life Manufacturing Equity Fund Direct-Growth | 0.86% | 0 | -0.02% | 0.00% | |
| Aditya Birla Sun Life Mid Cap Direct Fund-Growth | 0.00% | 0 | 0.00% | 0.00% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
